The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm

Wei Ting Chiu\textsuperscript{1,2,3*}, Chien Tai Hong\textsuperscript{1,2,3*}, Nai Fang Chi\textsuperscript{1,2,3}, Chaur Jong Hu\textsuperscript{1,2,3}, Han Hwa Hu\textsuperscript{1,2,3}, Lung Chan\textsuperscript{1,2,3*}

\textsuperscript{1} Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, \textsuperscript{2} Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, \textsuperscript{3} Stroke Centre, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

\* These authors contributed equally to this work.
\* cjjustinmd@gmail.com

\textbf{Abstract}

\textbf{Background}

The presence of an intracranial aneurysm is contraindicated to recombinant tissue plasminogen activator (r-PA) treatment for acute ischemic stroke. However, it is difficult to exclude asymptomatic intracranial aneurysms by using conventional, noncontrast head computed tomography (CT), which is the only neuroimaging suggested before r-PA. Recent case reports and series have shown that administering r-PA to patients with a pre-existing aneurysm does not increase the bleeding risk. However, Asians are known to have a relatively higher bleeding risk, and little evidence is available regarding the risk of using r-PA on Asian patients with intracranial aneurysms.

\textbf{Methods}

Medical records from the Shuang Ho hospital stroke registration between July 2010 and December 2014 were retrospectively reviewed, and 144 patients received r-PA. Unruptured intracranial aneurysms were detected using CT, or magnetic resonance or conventional angiography after r-PA. The primary and secondary outcomes were the difference in overall intracranial hemorrhage (ICH) and symptomatic ICH after r-PA. The differences were analyzed using Fisher’s exact or Mann–Whitney U tests, and $p < 0.05$ was defined as the statistical significance.

\textbf{Results}

A total of 144 patients were reviewed, and incidental unruptured intracranial aneurysms were found in 11 of them (7.6%). No significant difference was observed in baseline demographic data between the aneurysm and nonaneurysm groups. Among patients with an unruptured aneurysm, two had giant aneurysms (7.7 and 7.4 mm, respectively). The
bleeding risk was not significant different between aneurysm group (2 out of 11, 18%) with nonaneurysm group (7 out of 133, 5.3%) \( (p = 0.14) \). None of the patients with an unruptured aneurysm had symptomatic ICH, whereas one patient without an aneurysm exhibited symptomatic ICH.

**Conclusions**

The presence of an unruptured intracranial aneurysm did not significantly increase the risk of overall and symptomatic ICH in Taiwanese patients after they received r-tPA.

**Introduction**

Intracranial hemorrhage (ICH) is an unfavorable and potentially fatal complication of thrombolytic therapy based on recombinant tissue plasminogen activator treatment (r-tPA) in patients with acute ischemic stroke [1, 2]. According to guidelines from the Stroke Council of the American Heart Association/American Stroke Association (AHA/ASA), serial exclusion criteria are set to avoid the administration of r-tPA in patients with a high risk of post-r-tPA ICH, such as those with uncontrolled high blood pressure, coagulopathy, and a history of ICH [3, 4]. Patients with intracranial aneurysms are also excluded from receiving r-tPA because r-tPA is suspected to increase the risk of aneurysm rupture and bleeding [5].

The prevalence of intracranial aneurysms is approximately 3.7%–6.6% in the general population globally, most of which are asymptomatic [6, 7]. People are usually unaware of the problem until bleeding, rupture, or incidental detection through cerebral angiography. However, according to the AHA/ASA guidelines, only noncontrast computed tomography (CT) is suggested before the administration of r-tPA, which is unable to exclude intracranial aneurysms. Because the presence of an intracranial aneurysm is contraindicated to r-tPA (and because the earlier the r-tPA is administered, the more favorable is the outcome of recovery), physicians struggle with the dilemma of performing either CT or magnetic resonance (MR) angiography to exclude the possibility of intracranial aneurysms, or shortening the interval between the onset of stroke and the application of r-tPA but omitting this contraindication.

Some case reports have discussed the safety of applying r-tPA to patients with unruptured intracranial aneurysms [8, 9]. In particular, some have demonstrated the bleeding risk of administering r-tPA in patients with unruptured intracranial aneurysm. The risk of overall and symptomatic ICH after receiving r-tPA is identical to that of the nonaneurysm group [10–12]. However, the results from these series do not agree with the guidelines, and physicians still face a similar conflict. Hence, more series from different countries around the world are required. The present study retrospectively analyzed all of the patients with ischemic stroke from a single center in Taiwan who received r-tPA, and addressed the treatment conflict in clinical practice.

**Materials and methods**

**Patient selection**

This study was approved by the Joint Institutional Review Board of Taipei Medical University (TMU-JIRB) (201503027). Informed consent was waived which was agreed by TMU-JIRB. Medical records of stroke registration between July 2010 and December 2014 from the Shuang Ho hospital, a medical-university-affiliated hospital, were retrospectively reviewed. During
In this period, 2008 acute cerebral infarction cases were registered, and 146 of them received r-tPA. Intravenous thrombolytic therapy was provided by following the standard protocol adopted from the AHA/ASA guidelines. All patients had received a noncontrast head CT before r-tPA. A history of intracranial aneurysm or any suspicious aneurysm accidentally found during baseline CT was contraindicated to thrombolytic therapy. We excluded two patients because they received intra-arterial thrombolysis after intravenous thrombolysis (bridging therapy). The dosage of intravenous r-tPA thrombolysis was 0.9 mg/kg, and all of the patients received treatment within 3 h of the onset of stroke. Additionally, either head CT with CT angiography or brain MR imaging with MR angiography were performed within 72 h of thrombolysis. Intracranial aneurysms were identified through either CT/MR angiography or further conventional angiography.

Age; sex; National Institutes of Health Stroke Scale (NIHSS) scores before and after r-tPA; and the location, size, and morphology of patients’ aneurysms were recorded. The primary outcome of this study was determining the difference in overall ICH rates following thrombolytic therapy between two groups: patients with and without an intracranial aneurysm. The secondary outcome was understood the difference in symptomatic ICH between the two groups. Symptomatic ICH was defined according to the criteria of the European Cooperative Acute Stroke Study II [13], or by the NIHSS score increasing by more than 4 points. All of the CT/MR and CT/MR/conventional angiography results were analyzed by two independent neurologists.

Statistical analyses

All analyses were performed using SPSS (version 18.0 edition; SPSS Inc., Chicago, IL, USA) for Windows 10. The continuous variables were presented as mean ± standard deviation, and the categorical variables were calculated as percentages with corresponding 95% confidence intervals. The differences were analyzed using Fisher’s exact test or Mann–Whitney U test as appropriate. A p value of <0.05 was considered statistically significant.

Results

A total of 144 patients who had had a stroke and had received intravenous r-tPA within 3 h were enrolled. All of the patients had received either brain MR imaging and angiography or CT and CT angiography within 72 hours following r-tPA. No significant differences in the baseline clinical characteristics (age, sex, vascular risk factors, smoking, and NIHSS score before r-tPA) were observed, including between the two groups (Table 1). Incidental unruptured intracranial aneurysms were detected in 11 of the patients, and all of the unruptured aneurysms were confirmed by either MR, CT, or conventional angiography (Table 2). Nine unruptured aneurysms were at anterior circulation, and two were at posterior circulation; additionally, two of the patients exhibited a giant unruptured aneurysm (diameter ≥ 7 mm). Two (18.2%) of the patients with an unruptured aneurysm also had ICH, and the diameter of their aneurysms was 2.5 and 2 mm. Notably, the ICH episodes that occurred in the aneurysm group were not related to the location of aneurysm (Fig 1 and S1 and S2 Figs), and neither of these patients had symptomatic ICH. In the nonaneurysm group, seven out of the 133 patients (5.3%) had ICH and one had symptomatic ICH (Table 3). No significant difference in ICH and symptomatic ICH risk was observed between the aneurysm and nonaneurysm groups (both p > 0.05) (Table 4). The presence of unruptured intracranial aneurysm was not correlated with overall and symptomatic ICH (S1 Table).
The present study demonstrated that the presence of an unruptured intracranial aneurysm did not significantly increase the risk of overall and symptomatic ICH in Taiwanese patients with acute ischemic stroke after they had received r-tPA. Among the patients with complicated post-thrombolytic ICH, the location of their unruptured aneurysm was not associated with ICH. Therefore, the results hinted that the presence of an intracranial aneurysm may not require exclusion from intravenous thrombolytic treatment.

A giant aneurysm (diameter ≥ 7 mm), posterior circulation location, female sex, and smoking are associated with a higher risk of cerebral aneurysm rupture [9]. Thrombolytic agents alter the vascular permeability of the vascular basal lamina and the conformation of blood vessel endothelium and basilar membrane, which can weaken the defective vascular wall of an aneurysm and thus induce rupture and hemorrhage [15, 16]. Based on this concern, the presence of an intracranial aneurysm contraindicates thrombolytic therapy for acute ischemic stroke [13, 17]. Practically, however, exclusion on the basis of a silent intracranial aneurysm...
before administering r-tPA is difficult. First, in the general population, the prevalence of intra-
cranial aneurysms is approximately 3.7%–6.6%. Patients with a history of hypertension are
more likely to have intracranial aneurysms and are also at a higher risk of ischemic stroke.
However, most of these unruptured aneurysms are asymptomatic and people are unaware of
them. Second, the therapeutic interval between the onset of stroke and thrombolytic r-tPA for
Fig 1. Representative images of patients with intracranial aneurysm with a complicated post-r-tPA
intracranial hemorrhage. (A–C) The 72-year-old man had acute ischemic stroke and had received r-tPA
within 3 h after the onset of stroke. Follow-up diffusion-weighted imaging (A) (2 h after r-tPA) revealed acute
ischemic stroke over the left middle cerebral artery territory. (B) Magnetic resonance angiography revealed a
small (2 mm) saccular form of intracranial aneurysm (arrow) over the left internal carotid artery (Source
images of magnetic resonance angiography is available in the S1 Fig). (C) Follow-up computed tomography
performed 2 days after r-tPA demonstrated petechial hemorrhage in the infarcted margin. (D–F) The 77-year-
old woman had acute ischemic stroke and had received r-tPA within 3 h after the onset of stroke. Follow-up
diffusion-weighted imaging (D) (2 days after r-tPA) revealed acute ischemic stroke over the left middle
cerebral artery territory. (E) Magnetic resonance angiography revealed a small (2.5 mm) saccular form of
intracranial aneurysm (arrow) over the left internal carotid artery (Source images of magnetic resonance
angiography is available in the S2 Fig). (F) T2-weighted image demonstrated petechial hemorrhage over the
infarcted areas without mass effect.

https://doi.org/10.1371/journal.pone.0180021.g001

Table 3. Clinical information about the patients with ICH after r-tPA treatment.

| Patients of ICH | Aneurysm (location/size) | Location of stroke | Location of ICH | Type of ICH (ECASS-II)[14] | Management of ICH |
|----------------|--------------------------|--------------------|-----------------|---------------------------|------------------|
| 1              | N                        | Rʻ1 BG             | Rʻ1 BG          | PH1                       | M                |
| 2              | N                        | Rʻ1 P              | Rʻ1 P           | HI2                       | M                |
| 3              | N                        | Rʻ1 T-P            | Rʻ1 T-P         | HI2                       | M                |
| 4              | N                        | Lʻ1 F-T-P          | Lʻ1 F-T-P       | HI1                       | M                |
| 5              | N                        | Rʻ1 BG             | Bil F           | PH1                       | M                |
| 6              | N                        | Rʻ1 F              | Rʻ1 F-P         | PH2                       | S                |
| 7              | N                        | Rʻ1 F              | Rʻ1 F           | HI2                       | M                |
| 8              | Y (Lʻ1 ICA/2.5mm)        | Lʻ1 O-P            | Lʻ1 O-P         | HI2                       | M                |
| 9              | Y (Lʻ1 ICA/2mm)          | Lʻ1 P              | Lʻ1 P           | HI1                       | M                |

Note: BG, basal ganglia; ECASS-II, European Cooperative Acute Stroke Study II (hemorrhagic infarction types 1 and 2 (HI1 and HI2) and parenchymal hematoma types 1 and 2 (PH1 and PH2)); F, frontal lobe; ICA, internal carotid artery; ICH, intracranial hemorrhage, M, medical treatment; O, occipital lobe; P, parietal lobe; S, surgical treatment.

https://doi.org/10.1371/journal.pone.0180021.t003
Table 4. Comparison of overall intracranial hemorrhage (ICH) and symptomatic ICH between patients with/without aneurysm.

|                  | Aneurysm (-) | Aneurysm (+) | p-value |
|------------------|--------------|--------------|---------|
| Without ICH      | 126          | 9            |         |
| Overall ICH      | 7            | 2            | 0.09    |
| Symptomatic ICH  | 1            | 0            | 1.00    |

https://doi.org/10.1371/journal.pone.0180021.t004

Accordingly, acute ischemic stroke is extremely short. To shorten the interval between the onset of stroke and initiation of treatment, noncontrast conventional head CT is the only suggested neuroimaging study, and detection of an intracranial aneurysm through CT is nearly impossible. Although contrast CT or MR imaging may be able to detect unruptured aneurysms, these methods require more time than noncontrast CT and may delay the treatment. Due to these limitations, excluding all asymptomatic intracranial aneurysms before the administration of r-tPA is nearly impossible.

Since r-tPA was approved for acute ischemic stroke, several case reports have demonstrated the effects of r-tPA on patients with asymptomatic cerebral aneurysms, which were detected during follow-up neuroimaging [18–24]. Some of these cases did not involve the complication of ICH during aneurysm rupture; other case series investigated the safety of r-tPA for patients with unruptured cerebral aneurysms, and noted that the asymptomatic and incidentally detected unruptured cerebral aneurysms did not increase the risk of post-r-tPA ICH [10–12, 25, 26]. However, most of the aforementioned studies were conducted in Western countries and included limited Asians, who tend to exhibit a higher risk of post-r-tPA ICH because of coagulation differences [27–29]. The present study, conducted in Taiwan, partially addresses this gap. Specifically, we found that the risk of post-r-tPA symptomatic ICH did not increase among the patients with intracranial aneurysms; moreover, in the patients with ICH, the location of their hemorrhage was not relevant to the aneurysm. These data indicate that even in Asians, incidental or asymptomatic cerebral aneurysms are safe for thrombolytic r-tPA at the onset of acute ischemic stroke. Taking these series and case reports together, we suggest that the presence of an unruptured intracranial aneurysm is not a contraindication of administering r-tPA for acute ischemic stroke.

The present study had some limitations. First, not all the cerebral aneurysms were detected using conventional angiography. The sensitivity of MR/CT angiography in detecting cerebral aneurysm is inferior to that of the conventional angiography, particularly for detecting small-sized aneurysms, and therefore, the overall number of aneurysms may be underestimated and their classifications may be biased. Although, smaller-sized (< 7 mm in diameter) aneurysms are less likely to rupture and cause bleeding, ICH may mask the aneurysm. Rupture and bleeding of aneurysms may also induce vasospasm and transient disappearance of the aneurysm, and ICH may lead to the underestimation of the aneurysm-related bleeding.

In conclusion, the present study demonstrated that incidental unruptured intracranial aneurysms did not increase the risk of ICH, particularly symptomatic ICH, after r-tPA for ischemic stroke in Taiwanese patients. To shorten the interval of the onset of stroke and the administration of r-tPA, and to avoid guideline violations by physicians, an amendment of the contraindications of r-tPA for patients with intracranial aneurysms should be considered.

**Supporting information**

S1 Fig. Image of a 72 years old man, post r-tPA ICH with unruptured aneurysm. (TIF)
**Acknowledgments**

We acknowledge Wallace Academic Editing for editing this manuscript.

**Author Contributions**

**Conceptualization:** WTC NFC LC.

**Data curation:** WTC CTH NFC CJH LC.

**Formal analysis:** WTC CTH NFC CJH HHH LC.

**Funding acquisition:** CJH HHH LC.

**Investigation:** WTC CTH NFC CJH HHH LC.

**Methodology:** WTC CTH NFC.

**Project administration:** WTC LC.

**Resources:** NFC CJH HHH LC.

**Software:** WTC LC.

**Supervision:** CJH HHH LC.

**Validation:** WTC CTH NFC CJH HHH LC.

**Visualization:** WTC CTH NFC CJH HHH LC.

**Writing – original draft:** WTC CTH NFC.

**Writing – review & editing:** WTC CTH NFC.

**References**

1. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007; 24(1):1–10. Epub 2007/05/24. https://doi.org/10.1159/000103110 PMID: 17519538.

2. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007; 38(8):2279–83. Epub 2007/07/21. https://doi.org/10.1161/STROKEAHA.107.487009 PMID: 17641238.

3. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005; 36(4):916–23. Epub 2005/04/01. https://doi.org/10.1161/01.STR.0000163257.66207.2d PMID: 15800252.

4. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3):870–947. Epub 2013/02/02. https://doi.org/10.1161/STR.0b013e318284056a PMID: 23370208.

5. Garibaldi AA, Krajer Z. Aneurysm sac re-expansion after thrombolysis. J Endovasc Ther. 2006; 13 (1):111–6. Epub 2006/02/01. https://doi.org/10.1583/05-1551.1 PMID: 16445315.

6. Viak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis.
Risk of r-IPA induced aneurysmal hemorrhage

1. Rinkel GJ, Dijibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke. 1998; 29(1):251–6. Epub 1998/01/28. PMID: 9445359.

2. Briose a Gaia D, Almeida A, Monteiro N, Paiva Nunes A, Ferreira P, Mendonça N, et al. Successful Thrombolysis despite Having an Incidental Unruptured Cerebral Aneurysm. Case Reports in Neurological Medicine. 2014; 2014:323049. https://doi.org/10.1155/2014/323049 PMID: 25525532

3. Yoneda Y, Yamamoto S, Hara Y, Yamashita H. Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke. Case Reports in Neurology. 2009; 1(1):20–3. https://doi.org/10.1159/000224714 PMID: 20847927

4. Edwards NJ, Kamel H, Josephson SA. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature. Stroke. 2012; 43(2):412–6. Epub 2011/12/14. https://doi.org/10.1161/STROKEAHA.111.634147 PMID: 22156701.

5. Kim JT, Park MS, Yoon W, Cho KH. Detection and significance of incidental unruptured cerebral aneurysms in patients undergoing intravenous thrombolysis for acute ischemic stroke. J Neuroimaging. 2012; 22(2):197–200. Epub 2010/12/15. https://doi.org/10.1111/j.1552-6569.2010.00560.x PMID: 21143548.

6. Sheth KN, Shah N, Morovati V, Hermann LD, Cronin CA. Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms. Neurocrit Care. 2012; 17(2):199–203. Epub 2012/07/04. https://doi.org/10.1007/s12028-012-9734-9 PMID: 22752394.

7. Hacker W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). The Lancet. 1998; 352(9136):1245–51. http://dx.doi.org/10.1016/S0140-6736(98)08020-9.

8. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32(2):438–41. Epub 2001/02/07. PMID: 11157179.

9. Derek L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. Journal of Neurology, Neurosurgery & Psychiatry. 2008; 79(10):1093–9. https://doi.org/10.1136/jnnp.2007.133371 PMID: 18223014

10. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998; 65(1):1–9. Epub 1998/07/17. PMID: 9667553.

11. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21):2019–26. Epub 1999/12/11. PMID: 10591364.

12. Wang HF, Chan CW, Chan HH, Hung HC. Asymptomatic cerebral aneurysm in stroke patients eligible for intravenous thrombolytic therapy. Acta Neurol Taiwan. 2013; 22(1):43–8. Epub 2013/03/13. PMID: 23479246.

13. Ganesalingam J, Redwood R, Jenkins I. Thrombolysis of an acute stroke presentation with an incidental unruptured aneurysm. JRSM Cardiovasc Dis. 2013; 2:2048004013478808. Epub 2013/11/01. https://doi.org/10.1177/2048004013478808 PMID: 24175080.

14. Haji F, van Adel B, Avery M, Megyesi J, Young GB. Intracranial aneurysm rupture following intravenous thrombolysis for stroke. Can J Neurol Sci. 2014; 41(1):95–8. Epub 2014/01/05. PMID: 24384346.

15. Xu M, Yan SQ, Cao J, Lou M. No hemorrhagic transformation after intravenous thrombolysis in a pontine infarction patient with basilar aneurysm. CNS Neurosci Ther. 2014; 20(5):473–5. Epub 2014/03/22. https://doi.org/10.1111/cns.12254 PMID: 24645906.

16. Rammos SK, Neils DM, Fraser K, Klopfenstein JD. Anterior communicating artery aneurysm rupture after intravenous thrombolysis for acute middle cerebral artery thromboembolism: case report. Neurosurgery. 2012; 70(6):E1603–7; discussion E7. Epub 2011/07/29. https://doi.org/10.1227/NEU.0b013e3182e1087 PMID: 21796012.

17. Yoneda Y, Yamamoto S, Hara Y, Yamashita H. Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke. Case Rep Neurol. 2009; 1(1):20–3. Epub 2009/01/01. https://doi.org/10.1159/000224714 PMID: 20847927.

18. Zaldivar-Jolissaint JF, Messerer M, Bervini D, Mosimann PJ, Levivier M, Daniel RT. Rupture of a concealed aneurysm after intravenous thrombolysis of a thrombus in the parent middle cerebral artery. J Stroke Cerebrovasc Dis. 2015; 24(3):e63–5. Epub 2014/12/30. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.10.004 PMID: 25542765.
25. Mowla A, Singh K, Mehla S, Ahmed MK, Shirani P, Kamal H, et al. Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm? Int J Stroke. 2015; 10 Suppl A100:113–8. Epub 2015/09/18. https://doi.org/10.1111/ijs.12616 PMID: 26377963.

26. Ding J, Han J, Jing Z, Jiang Y. Is it dangerous to treat acute ischemic stroke by thrombolytic therapy in patients with comorbid intracranial aneurysms? Am J Emerg Med. 2016; 34(3):636–42. Epub 2016/01/23. https://doi.org/10.1016/j.ajem.2015.12.025 PMID: 26795887.

27. Mehta RH, Cox M, Smith EE, Xian Y, Bhatt DL, Fonarow GC, et al. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014; 45(8):2263–9. Epub 2014/07/30. https://doi.org/10.1161/STROKEAHA.114.005019 PMID: 25070958.

28. Dharmasaroja PA, Muengtaweepongsa S, Dharmasaroja P. Intravenous thrombolysis in Thai patients with acute ischemic stroke: role of aging. J Stroke Cerebrovasc Dis. 2013; 22(3):227–31. Epub 2011/12/20. https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.08.001 PMID: 22177929.

29. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke. 2010; 41(5):885–90. Epub 2010/03/13. https://doi.org/10.1161/STROKEAHA.109.575605 PMID: 20224056.